29 November 2021, 08:45, Adelaide, Australia and Liege, Belgium – Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce the Therapeutic Goods Administration (TGA) has approved the novel combined oral contraceptive NEXTSTELLIS® (14.2 mg of estetrol and 3 mg drospirenone tablets). Mayne Pharma anticipates the commercial launch of NEXTSTELLIS by mid-2022 supported by healthcare professional market education from January 2022.
Liege, Belgium, November 29, 2021 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the holding of its Investor Day today at its R&D and production center, the Mithra CDMO in Flémalle, Belgium.
As of 9:00 am CET, all presentations can be simultaneously followed by webcast on the Company’s website or by clicking here. A replay will also be available via this same link shortly after the end of the conference.
Liege, Belgium, 10 November 2021 – 17:45 CET – In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the “Company” or “Mithra”) announces the below information, following the issuance of 314,162 new shares today for a total amount of EUR 5,727,177 following the Put Option Notice issued on July 2, 2021 in the framework of LDA capital.
Liege, Belgium, 10 November 2021 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it will host an Investor Day on Monday, November 29, 2021 at 9:00 am CET.
The event will be broadcasted live via webcast, the link will be available soon on Mithra’s website.
Rue Saint-Georges 5
Tel. : +32 (0)4 349 28 22
Fax : +32 (0)4 349 28 21
Email : firstname.lastname@example.org